Valuation: Invivyd, Inc.

Capitalization 416M 355M 325M 308M 569M 39.79B 572M 3.87B 1.51B 18.88B 1.56B 1.53B 65.63B P/E ratio 2026 *
-4.2x
P/E ratio 2027 * -3.45x
Enterprise value 416M 355M 325M 308M 569M 39.79B 572M 3.87B 1.51B 18.88B 1.56B 1.53B 65.63B EV / Sales 2026 *
4.9x
EV / Sales 2027 * 4.44x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Invivyd, Inc.

1 day-1.34%
1 week+0.68%
Current month+5.00%
1 month-14.53%
3 months-5.77%
6 months-16.95%
Current year-40.49%
1 week 1.42
Extreme 1.42
1.58
1 month 1.33
Extreme 1.332
1.8
Current year 1.17
Extreme 1.17
2.78
1 year 0.48
Extreme 0.483
3.07
3 years 0.35
Extreme 0.3546
5.2
5 years 0.35
Extreme 0.3546
78.82
10 years 0.35
Extreme 0.3546
78.82
Manager TitleAgeSince
Chief Executive Officer 53 29/05/2024
Chief Tech/Sci/R&D Officer 42 04/03/2026
Chief Tech/Sci/R&D Officer 57 11/04/2023
Director TitleAgeSince
Director/Board Member 70 30/09/2020
Director/Board Member 46 25/03/2025
Director/Board Member 45 21/06/2022
Change 5d. change 1-year change 3-years change Capi.($)
-1.34%+0.68%+70.75%+2.08% 421M
+2.61%+2.91%+36.15%+133.81% 883B
+2.75%+2.58%+55.23%+43.31% 540B
+0.31%+1.69%+10.90%+41.69% 367B
-0.94%-2.05%+21.74%+10.73% 328B
+0.13%+1.47%+35.23%+14.62% 288B
+0.78%+1.00%+29.63%+26.23% 283B
+0.96%-0.10%+48.05%-3.15% 278B
+0.91%+2.12%-31.78%-49.10% 206B
+0.05%+1.61%+24.40%+44.43% 181B
Average +0.40%+1.31%+30.03%+26.47% 335.41B
Weighted average by Cap. +0.69%+1.43%+30.59%+50.39%

Financials

2026 *2027 *
Net sales 84.83M 72.45M 66.38M 62.75M 116M 8.12B 117M 790M 308M 3.85B 318M 312M 13.39B 93.62M 79.96M 73.26M 69.26M 128M 8.96B 129M 872M 340M 4.25B 351M 344M 14.78B
Net income -88.7M -75.75M -69.4M -65.61M -121M -8.49B -122M -826M -322M -4.03B -333M -326M -14B -121M -103M -94.66M -89.49M -166M -11.58B -167M -1.13B -439M -5.49B -454M -444M -19.1B
Net Debt - -
Logo Invivyd, Inc.
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
Employees
122
Date Price Change Volume
13/05/26 1.470 $ -1.34% 1,962,366
12/05/26 1.490 $ -1.32% 1,028,848
11/05/26 1.510 $ +0.67% 2,834,879
08/05/26 1.500 $ +4.90% 1,467,748
07/05/26 1.430 $ -2.05% 2,143,785
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.470USD
Average target price
10.00USD
Spread / Average Target
+580.27%

Quarterly revenue - Rate of surprise